B of A Securities Downgrades HOOKIPA Pharma to Underperform, Lowers Price Target to $0.5
B of A Securities analyst Alec Stranahan downgrades HOOKIPA Pharma (NASDAQ:HOOK) from Buy to Underperform and lowers the price target from $6 to $0.5.
12 Health Care Stocks Moving In Friday’s After-Market Session
Gainers Brainstorm Cell (NASDAQ:BCLI) stock moved upwards by 20.6% to $2.05 during Friday’s after-market session. The market value…
Earnings Scheduled For November 14, 2022
Companies Reporting Before The Bell
• Opiant Pharma (NASDAQ:OPNT) is estimated to report quarterly loss at $1.49 per share on revenue of $3.68 million.
12 Health Care Stocks Moving In Thursday’s Pre-Market Session
Gainers
HOOKIPA Pharma (NASDAQ:HOOK) stock increased by 45.5% to $1.76 during Thursday's pre-market session. The market value of their outstanding shares is at $96.2 million.
Stocks That Hit 52-Week Lows On Wednesday
During Wednesday's trading, 517 companies set new 52-week lows.
Truist Securities Maintains Buy on HOOKIPA Pharma, Lowers Price Target to $11
Truist Securities analyst Asthika Goonewardene maintains HOOKIPA Pharma (NASDAQ:HOOK) with a Buy and lowers the price target from $16 to $11.
SVB Leerink Maintains Outperform on HOOKIPA Pharma, Lowers Price Target to $3
SVB Leerink analyst Andrew Berens maintains HOOKIPA Pharma (NASDAQ:HOOK) with a Outperform and lowers the price target from $4 to $3.
HOOKIPA Pharma Q2 EPS $(0.23) Beats $(0.36) Estimate, Sales $2.75M Miss $3.56M Estimate
HOOKIPA Pharma (NASDAQ:HOOK) reported quarterly losses of $(0.23) per share which beat the analyst consensus estimate of $(0.36) by 36.11 percent. This is a 55.77 percent increase over losses of $(0.52) per share from